Dynamics of Subclinical Malaria: Preliminary Study

Malaria Clinical Trial

Official title:

Preliminary Evaluation of Dynamics of Subclinical Malaria

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03483571
• Other study ID #: Pro00091895
• Status: Completed
• Start date: July 26, 2018
• Est. completion date: September 3, 2019

Study information

• Verified date: May 2021
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a short longitudinal preliminary study that aims to describe the dynamics of low-density subclinical malaria to support the final study design of a subsequent matched cohort study. The primary objective is to assess the dynamics of subclinical malaria detected by ultrasensitive PCR over a short duration. The results will be used to guide the design of a matched cohort study of subclinical malaria in Myanmar and along its borders with China and Bangladesh

Description:

This is a short longitudinal preliminary study that aims to describe the dynamics of low-density subclinical malaria to support the final study design of a subsequent matched cohort study. In this study, a small number of asymptomatic infections detected by ultrasensitive PCR (usPCR) will be followed and tested intensively for three months to measure the temporal dynamics of these infections. A much larger number of uninfected individuals will be followed for just 2-4 weeks (two visits), providing a comparator group for the infected cohort. The validity of our results in a subsequent matched cohort study depends, in part, on our ability to accurately classify infection status using a single usPCR result. In other words, do the investigators have sufficient confidence in the correct classification of malaria infection positive and negative status using usPCR test at the beginning of the study? While there is no gold standard test more sensitive than usPCR, repeated usPCR testing offers a surrogate. Presumably, in a low transmission setting, someone who is truly uninfected on the first testing should remain negative on multiple consecutive tests, but this remains to be confirmed.

The investigators will enroll study participants in up to six study sites, each with >2 villages, towns, unions, refugee camps or plantations, or a single military base. Alternative and additional sites may be added to ensure enough infected cases. The investigators will screen for eligibility (age at least 0.5 year; able & willing to strictly follow study protocol and to provide written informed consent or assent as appropriate) and enroll and consent eligible individuals. Study procedures are based on test results:

• RDT-positive: one-time enrollment for data and venous blood collection; Refer to and ensure appropriate treatment by care providing team; No study-related follow up

• RDT-negative: Collect data and DBS samples; Return to research clinic in 2-4 weeks

• PCR-negative participants: One follow up visit approximately 2-4 weeks after enrollment

• PCR-positive participants: Five follow up visits at approximately 4, 6, 8, 10, and 12 weeks (for those with total 12 weeks follow up) or 2, 3, 4, 5 and 6 weeks (for those with total 6 weeks follow up) after enrollment

• Finger stick blood sampling with be done for RDT and dried blood spot sampling in all participants at each scheduled and unscheduled visit.

• Venous sampling will be done for participants with RDT+ infections detected at times when study staff trained for venous sampling are present. Blood volumes at any time point are limited to 2 mL for children aged < 3 years, 3 mL for age 3-5 years, and 5 mL for older children and adults.

• Estimated duration of study:18 months

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2970
• Est. completion date: September 3, 2019
• Est. primary completion date: September 3, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Months and older

Eligibility

Inclusion Criteria:

• Age 6 months or older at the time of screening; Written informed consent obtained (from the parent/guardian if the subject is less than 18 years old).

Exclusion Criteria:

Any condition which in the view of the investigator makes participation not in the best interests of the prospective participant. Any condition that would interfere with study participation or pose risks to participants. Those with clinical malaria infection as diagnosed by positive RDT may be invited to return and be re-screened for study eligibility after treatment and resolution of their illness.

Related Conditions & MeSH terms

• Malaria

Locations

Country	Name	City	State
Myanmar	Department of Medical Research	Yangon

Sponsors (5)

Lead Sponsor	Collaborator
Duke University	Defence Services Medical Research Center, Myanmar, International Centre for Diarrhoeal Disease Research, Bangladesh, Ministry of Health and Sports, Myanmar, National Institute of Parasitic Diseases, China CDC

Country where clinical trial is conducted

Myanmar, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of individuals with initially positive usPCR tests that were followed by 1 or more consecutive positive tests on weekly or biweekly testing	Proportion of individuals with initially positive usPCR	12 weeks
Primary	Proportion of individuals with initially negative usPCR tests that subsequently had at least one usPCR positive test at a second screening 4 weeks later	Proportion of individuals with initially negative usPCR tests	4 weeks
Secondary	Incidence of falciparum malaria infection by RDT	Incidence of falciparum malaria infection by RDT	2 years
Secondary	Incidence of vivax malaria infection by RDT	Incidence of vivax malaria infection by RDT	2 years
Secondary	Incidence of mixed falciparum/vivax malaria infection by RDT	Incidence of mixed falciparum/vivax malaria infection by RDT	2 years
Secondary	Incidence of falciparum malaria infection by usPCR	Incidence of falciparum malaria infection by usPCR	2 years
Secondary	Incidence of vivax malaria infection by usPCR	Incidence of vivax malaria infection by usPCR	2 years
Secondary	Incidence of mixed falciparum/vivax malaria infection by usPCR	Incidence of mixed falciparum/vivax malaria infection by usPCR	2 years
Secondary	Seroreactivity to polymorphic malaria/mosquito proteins	Seroreactivity to polymorphic malaria/mosquito proteins	2 years